methyl N-[(10R,14S)-14-[4-(3-chloro-2,6-difluorophenyl)-6-oxo-2,3-dihydropyridin-1-yl]-17-fluoro-10-methyl-9-oxo-8-azatricyclo[13.3.1.02,7]nonadeca-1(19),2(7),3,5,15,17-hexaen-5-yl]carbamate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: methyl N-[(10R,14S)-14-[4-(3-chloro-2,6-difluorophenyl)-6-oxo-2,3-dihydropyridin-1-yl]-17-fluoro-10-methyl-9-oxo-8-azatricyclo[13.3.1.02,7]nonadeca-1(19),2(7),3,5,15,17-hexaen-5-yl]carbamate
• 化学式: C₃₂H₂₉ClF₃N₃O₄
• 分子量: 612.0
• InChiKey: DGWYVGZPSGGKME-CRYYWNKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  43
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150166550A1

  公开（公告）日：2015-06-18

  The present invention provides compounds of Formula (VIII): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供公式（VIII）的化合物：或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如定义所述。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肌酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• POLYCARBONATE RESIN COMPOSITION AND TRANSPARENT FILM
  申请人：Mitsubishi Chemical Corporation

  公开号：EP2881771A1

  公开（公告）日：2015-06-10

  A transparent film obtained by molding a polycarbonate resin composition comprising 100 parts by weight of (A) a polycarbonate resin containing (a) a structural unit derived from a dihydroxy compound represented by the following formula (1) and (b) a structural unit derived from a dihydroxy compound having an ether ring, and from 0.1 to 10 parts by weight of (B) a resin having a composition different from that of the polycarbonate resin (A), with the absolute value of the difference in the glass transition temperature between the resin (B) and the polycarbonate resin (A) being 80°C or less and the absolute value of the difference in the refractive index being 0.02 or less, wherein in the transparent film, the ratio of the retardation measured at a wavelength of 450 nm to the retardation measured at a wavelength of 550 nm satisfies a specific formula.

  一种通过模塑聚碳酸酯树脂组合物而获得的透明薄膜，该组合物包含 100 重量份的(A)聚碳酸酯树脂，其中含有(a)衍生自下式(1)代表的二羟基化合物的结构单元和(b)衍生自具有醚环的二羟基化合物的结构单元，以及 0.1 至 10 重量份的(B)树脂，其组成不同于聚碳酸酯树脂(A)，树脂(B)与聚碳酸酯树脂(A)之间的玻璃化转变温度差的绝对值为 80°C 或更低，折射率差的绝对值为 0.02 或更低，其中在透明薄膜中，波长为 450 纳米时测得的延迟与波长为 550 纳米时测得的延迟之比满足特定的式子。
• DIHYDROPYRIDONE AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2882734B1

  公开（公告）日：2016-10-12
• US9376444B2
  申请人：——

  公开号：US9376444B2

  公开（公告）日：2016-06-28
• [EN] DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS<br/>[FR] RÉCEPTEURS P1 DE LA DIHYDROPYRIDONE EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014022766A1

  公开（公告）日：2014-02-06

  The present invention provides compounds of Formula (VIII): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.